Table 1 Clinicopathological parameters compared to ADAM33 promoter methylation analyzed by Chi-square Test or Fisher's Exact Test.
Variate | n a (%) | ADAM33Methylation (%) | p-value | |
|---|---|---|---|---|
| Â | Â | Positive | Negative | Â |
Tumor Stage | Â | Â | Â | Â |
0/I | 14 (20.0) | 4 (28.6) | 10 (71.4) | 0.641 |
II | 33 (47.1) | 14 (42.4) | 19 (57.6) | Â |
III/IV | 23 (32.9) | 8 (34.8) | 15 (65.2) | Â |
Tumor Size b | Â | Â | Â | Â |
pT1/pTis | 20 (27.4) | 6 (30.0) | 14 (70.0) | 0.174 |
pT2 | 38 (52.1) | 14 (36.8) | 24 (63.2) | Â |
pT3/pT4 | 15 (20.5) | 9 (60.0) | 6 (40.0) | Â |
Histological Grade (SBR) | Â | Â | Â | Â |
I | 19 (27.1) | 8 (42.1) | 11 (57.9) | 0.799 |
II | 33 (47.1) | 14 (42.4) | 19 (57.6) | Â |
III | 18 (25.7) | 6 (33.3) | 12 (66.7) | Â |
Lymph Node Status | Â | Â | Â | Â |
Negative | 34 (47.9) | 13 (38.2) | 21 (61.8) | 0.965 |
Positive | 37 (52.1) | 15 (40.5) | 22 (59.5) | Â |
Estrogen Receptor Status (ER) | Â | Â | Â | Â |
Negative | 12 (17.1) | 4 (33.3) | 8 (66.7) | 0.751 |
Positive | 58 (82.9) | 24 (41.4) | 34 (58.6) | Â |
ERBB2 Status | Â | Â | Â | Â |
Negative | 43 (66.2) | 18 (41.9) | 25 (58.1) | 0.378 |
Positive | 22 (33.8) | 6 (27.3) | 16 (72.7) | Â |
Progesterone Receptor Status (PR) | Â | Â | Â | Â |
Negative | 15 (24.6) | 4 (26.7) | 11 (73.3) | 0.678 |
Positive | 46 (75.4) | 17 (36.9) | 29 (63.1) | Â |
Metastasis Status | Â | Â | Â | Â |
Negative | 55 (79.7) | 23 (41.8) | 32 (58.2) | 0.548 |
Positive | 14 (20.3) | 4 (28.6) | 10 (71.4) | Â |
Recurrence Status | Â | Â | Â | Â |
Negative | 63 (91.3) | 23 (36.5) | 40 (63.5) | 0.201 |
Positive | 6 (8.7) | 4 (66.7) | 2 (33.3) | Â |
Histological Tumor Type | Â | Â | Â | Â |
Invasive Ductal Carcinoma | 51 (70.8) | 13 (25.5) | 38 (74.5) | 0.0002 |
Invasive Lobular Carcinoma | 21 (29.2) | 16 (76.2) | 5 (23.8) | Â |